Search results for "EMA"

Article Quality by Design—Bridging the Gap between Concept and Implementation
A relatively small number of marketing approval applications made in Europe have supporting QbD data, with EMA conceding that application dossiers with QbD information are far from becoming a standard…

Article Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability
There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA). The meeting, held in October 2013, wa…

Article Ensuring Viral Safety of Viral Vaccines and Vectors
In a US National Institutes of Health study, lead investigator Rebecca Sheets, PhD, systematically characterized the breadth and sensitivity of routine in-vitroand in-vivoassays for inapparent viruses…

Article An Integrated Approach to Ensure the Viral Safety of Biotherapeutics
EMA, Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products (London, May 30, 2013). 2. EMA, Requirements and Controls Applied to Bovine Serum Us…

Article Ensuring the Quality of Biologicals
As stated in the European Medicines Agency (EMA) Guideline on Similar Biological Medicinal Products (1), “Comparability studies are needed to generate evidence substantiating the similar nature, in te…

Article The Bullish Outlook for Biosimilars
Yet questions and uncertainties remain, and the path forward likely holds some surprises. Update on the Global Biosimilar Market The magnitude of the biosimilar market’s true potential can…

Article Global Expansion Shapes Drug Oversight
At the same time, FDA and the European Medicines Agency (EMA) annouced plans to expand their many collaborative programs, including renewal of a pilot program that allows for parallel review and consu…

Article Design and Qualification of Single-Use Systems
International Council for Harmonization (ICH) Q7, European Medicines Agency (EMA) Q7, and FDA Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients incorporate essentially…

Article GMP Challenges for Advanced Therapy Medicinal Products
“ATMPs are complex pharmaceuticals, for which traditional approaches may not be possible,” Paula Salmikangas, chair of the EMA’s committee for advanced therapies (CAT), told an European Directorate fo…

Article Monoclonal Antibodies Key to Unlocking the Biosimilars Market
The European Medicines Agency (EMA) approved the first mAb biosimilar developed by Celltrion and Hospira in 2013 (infliximab: Remsima/Inflectra). Development of clear, regulatory approval pathways for…

Previous PageNext Page